IDEAYA Biosciences, Inc. (IDYA)

Market Cap	854.98M
Revenue (ttm)	49.87M
Net Income (ttm)	-52.67M
Shares Out	40.30M
EPS (ttm)	-1.48
PE Ratio	n/a
Forward PE	4.65
Dividend	n/a
Ex-Dividend Date	n/a

Volume	421,859
Open	17.67
Previous Close	17.77
Day's Range	17.25 - 18.2
52-Week Range	8.14 - 24.09
Beta	0.98
Analysts	Buy
Price Target	24.61 (+36.9%)
Earnings Date	Nov 21, 2022

About IDYA

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers ha...

• Industry: Biotechnology
• IPO Date: May 23, 2019
• CEO: Yujiro Hata
• Employees: 95
• Stock Exchange: NASDAQ
• Ticker Symbol: IDYA

Full Company Profile

Financial Performance

In 2021, IDYA's revenue was $27.94 million, an increase of 43.01% compared to the previous year's $19.54 million. Losses were -$49.76 million, 44.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for IDYA stock is "Buy." The 12-month stock price forecast is 24.61, which is an increase of 36.87% from the latest price.

Price Target

$24.61

(36.87% upside)

Analyst Consensus: Buy

Stock Forecasts